rs184043065
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_StrongBP6BS2_Supporting
The NM_017433.5(MYO3A):c.3538G>A(p.Glu1180Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000981 in 1,614,116 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_017433.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYO3A | NM_017433.5 | c.3538G>A | p.Glu1180Lys | missense_variant | 30/35 | ENST00000642920.2 | NP_059129.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYO3A | ENST00000642920.2 | c.3538G>A | p.Glu1180Lys | missense_variant | 30/35 | NM_017433.5 | ENSP00000495965.1 | |||
MYO3A | ENST00000543632.5 | c.1777-38041G>A | intron_variant | 1 | ENSP00000445909.1 | |||||
MYO3A | ENST00000647478.1 | n.*1393+3263G>A | intron_variant | ENSP00000493932.1 |
Frequencies
GnomAD3 genomes AF: 0.000736 AC: 112AN: 152180Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000609 AC: 153AN: 251206Hom.: 0 AF XY: 0.000611 AC XY: 83AN XY: 135814
GnomAD4 exome AF: 0.00101 AC: 1472AN: 1461818Hom.: 2 Cov.: 32 AF XY: 0.000982 AC XY: 714AN XY: 727200
GnomAD4 genome AF: 0.000735 AC: 112AN: 152298Hom.: 0 Cov.: 32 AF XY: 0.000564 AC XY: 42AN XY: 74472
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:1
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | MYO3A: BP4, BS1:Supporting - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 22, 2023 | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 1180 of the MYO3A protein (p.Glu1180Lys). This variant is present in population databases (rs184043065, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with MYO3A-related conditions. ClinVar contains an entry for this variant (Variation ID: 178468). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MYO3A protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 29, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 03, 2021 | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Autosomal recessive nonsyndromic hearing loss 30 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 05, 2022 | The MYO3A c.3538G>A; p.Glu1180Lys variant (rs184043065), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: 178468). This variant is found in the non-Finnish European population with an allele frequency of 0.098% (126/129,020 alleles) in the Genome Aggregation Database. The glutamic acid at codon 1180 is weakly conserved, and computational analyses predict that this variant is neutral (REVEL: 0.131). Due to limited information, the clinical significance of the p.Glu1180Lys variant is uncertain at this time. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 17, 2022 | The c.3538G>A (p.E1180K) alteration is located in exon 30 (coding exon 28) of the MYO3A gene. This alteration results from a G to A substitution at nucleotide position 3538, causing the glutamic acid (E) at amino acid position 1180 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 04, 2016 | p.Glu1180Lys in exon 30 of MYO3A: This variant is not expected to have clinical significance because it has been identified in 0.2% (10/6614) of Finnish chromos omes and in 0.1% (69/66376) of European chromosomes by the Exome Aggregation Con sortium (ExAC, http://exac.broadinstitute.org; dbSNP rs184043065). In addition, the glutamine (Glu) residue at position 1180 is not conserved across species an d computational analyses (biochemical amino acid properties, AlignGVGD, PolyPhe n2, and SIFT) suggest that the Glu1180Lys variant may not impact the protein. Of note, horse has a lysine (Lys) at this position. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at